Cristiana Sessa
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial
Froesch P, Früh M, Gautschi O, Sessa C, König D, Metaxas Y, Colombo I, Schmid S, Oppliger Leibundgut E, Rusterholz C, Godar G, Li Q, Rothschild S, Mark M, Swiss Group for Clinical Cancer Research (SAKK). Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. Lung Cancer 2021; 156:91-99.
Apr 25, 2021Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial
Apr 25, 2021Lung Cancer 2021; 156:91-99
Froesch Patrizia, Früh Martin, Gautschi Oliver, Sessa Cristiana, König David, Metaxas Yannis, Colombo Ilaria, Schmid Sabine, Oppliger Leibundgut Elisabeth, Rusterholz Corinne, Godar Gilles, Li Qiyu, Rothschild Sacha I, Mark Michael, Swiss Group for Clinical Cancer Research (SAKK)
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors
Jörger M, Sessa C, Stuedeli S, Levy N, Hafner P, Lane H, Larger P, Engelhardt M, Kaindl T, Volden M, Mark M, Mantiero M, Hess D, Metaxas Y, Stathis A, von Moos R. A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors. Invest New Drugs 2019
Aug 30, 2019A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors
Aug 30, 2019Invest New Drugs 2019
Jörger Markus, Sessa Cristiana, Stuedeli Silvia, Levy Nicole, Hafner Peter, Lane Heidi, Larger Patrice, Engelhardt Marc, Kaindl Thomas, Volden Matthias, Mark Michael, Mantiero Mara, Hess Dagmar, Metaxas Yannis, Stathis Anastasios, von Moos Roger
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
Wicki A, Tzankov A, Hess V, Childs A, Hierro C, Rodón J, Hess D, Jörger M, von Moos R, Sessa C, Ritschard R, Prêtre V, Herrmann R, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanović N, Cmiljanović V, Stumm M, Dimitrijević S, Kristeleit R. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). Eur J Cancer 2018; 96:6-16.
Apr 13, 2018First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
Apr 13, 2018Eur J Cancer 2018; 96:6-16
Wicki Andreas, Tzankov Alexandar, Hess Viviane, Childs Alexa, Hierro Cinta, Rodón Jordi, Hess Dagmar, Jörger Markus, von Moos Roger, Sessa Cristiana, Ritschard Reto, Prêtre Vincent, Herrmann Richard, Brown Nicholas, Xyrafas Alexandros, Bize Vincent, Hawle Hanne, Berardi Simona, Cmiljanović Nataša, Cmiljanović Vladimir, Stumm Michael, Dimitrijević Saša, Kristeleit Rebecca
Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients
Zweifel M, Sessa C, Schoenfeld W, Tapia C, Brauchli P, Hawle H, Pilop C, Rothgiesser K, Bigler M, Pagani O, von Moos R, Weder P, Riniker S, Thürlimann B. Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients. Endocr Connect 2017; 6:549-556.
Aug 16, 2017Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients
Aug 16, 2017Endocr Connect 2017; 6:549-556
Zweifel Martin, Sessa Cristiana, Schoenfeld Wolfgang, Tapia Coya, Brauchli Peter, Hawle Hanne, Pilop Christiane, Rothgiesser Karin M, Bigler Martin, Pagani Olivia, von Moos Roger, Weder Patrik, Riniker Salome, Thürlimann Beat
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
Kunstfeld R, Moser E, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori F, Pfeilstöcker M, Raut C, Michielin O, Meran J, Lenz H, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer P, Markham M, Markman B, Mayerhoefer M, Remick S, Robson M, Rutkowski P, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber J, Wildiers H, Strasser F, Stiefel F, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll H, Schnipper L, Sessa C, Shapiro C, Steele J, Sternberg C, Yarden Y, Dittrich C, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close J, Coiffier B, Connolly R, Coupland S, Banerjee S, Awada A, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz J, Österlund P, Pavlidis N, Purkalne G, De Petris L, De Santis M, de Vries E, Hahn S, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones D, Jost L, Keilholz U, Khan S, Kiss A, Grothey A, Gopalan P, Dizon D, Duff J, Duska L, Eniu A, Ernstoff M, Felip E, Fey M, Gilbert J, Girard N, Glaudemans A, Köhne C. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open 2016; 1:e000097.
Sep 29, 2016ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
Sep 29, 2016ESMO Open 2016; 1:e000097
Kunstfeld Rainer, Moser Elizabeth Charlotte, Mountzios Giannis, Moynihan Timothy, Nielsen Torsten, Ohe Yuichiro, Öberg Kjell, Palumbo Antonio, Peccatori Fedro Alessandro, Pfeilstöcker Michael, Raut Chandrajit, Michielin Olivier, Meran Johannes G, Lenz Heinz-Josef, Lichtman Stuart, Licitra Lisa, Lion Thomas, Litière Saskia, Liu Lifang, Loehrer Patrick J, Markham Merry Jennifer, Markman Ben, Mayerhoefer Marius, Remick Scot C, Robson Mark, Rutkowski Piotr, Stupp Roger, Sullivan Richard, Tabernero Josep, Travado Luzia, Verheij Marcel, Voest Emile, Vokes Everett, Von Roenn Jamie, Weber Jeffrey S, Wildiers Hans, Strasser Florian, Stiefel Friedrich, Salgado Roberto, Schapira Lidia, Schernhammer Eva, Schlumberger Martin, Schmoll Hans-Joachim, Schnipper Lowell, Sessa Cristiana, Shapiro Charles L, Steele Julie, Sternberg Cora N, Yarden Yosef, Dittrich Christian, Bhatia Smita, Bogaerts Jan, Buckner Jan, Cardoso Fatima, Casali Paolo, Chu Edward, Close Julia Lee, Coiffier Bertrand, Connolly Roisin, Coupland Sarah, Banerjee Susana, Awada Ahmad, Kosty Michael, Jezdic Svetlana, Pyle Doug, Berardi Rossana, Bergh Jonas, El-Saghir Nagi, Lotz Jean-Pierre, Österlund Pia, Pavlidis Nicholas, Purkalne Gunta, De Petris Luigi, De Santis Maria, de Vries Elisabeth G E, Hahn Stephen M, Hanna Diana, Herold Christian, Herrstedt Jørn, Homicsko Krisztian, Jones Dennie V, Jost Lorenz, Keilholz Ulrich, Khan Saad, Kiss Alexander, Grothey Axel, Gopalan Priya K, Dizon Don S, Duff Jennifer, Duska Linda R, Eniu Alexandru, Ernstoff Marc, Felip Enriqueta, Fey Martin F, Gilbert Jill, Girard Nicolas, Glaudemans Andor W J M, Köhne Claus-Henning
Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors
Lennerz V, Woelfel T, Forssmann U, Zieschang J, Gnad-Vogt U, Ochsenbein A, Knuth A, von Boehmer L, Hess D, Boehm S, Mach N, Sessa C, Gallerani E, Gross S, Kaempgen E. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunol Immunother 2014; 63:381-94.
Feb 2, 2014Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors
Feb 2, 2014Cancer Immunol Immunother 2014; 63:381-94
Lennerz Volker, Woelfel Thomas, Forssmann Ulf, Zieschang Juergen, Gnad-Vogt Ulrike, Ochsenbein Adrian F, Knuth Alexander, von Boehmer Lotta, Hess Dagmar, Boehm Steffen, Mach Nicolas, Sessa Cristiana, Gallerani Elisa, Gross Stefanie, Kaempgen Eckhart
T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein
Laurent J, Gnad-Vogt U, Stupp R, Quaratino S, Sessa C, Omlin A, Beck J, Gallerani E, Liedert B, Ongarello S, Bertrand C, Vicari M, Joffraud M, Gillessen Sommer S, Touvrey C, Speiser D. T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. J Transl Med 2013; 11:5.
Jan 7, 2013T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein
Jan 7, 2013J Transl Med 2013; 11:5
Laurent Julien, Gnad-Vogt Ulrike S, Stupp Roger, Quaratino Sonia, Sessa Cristiana, Omlin Aurelius, Beck Joachim, Gallerani Elisa, Liedert Bernd, Ongarello Stefano, Bertrand Caroline, Vicari Manuela, Joffraud Magali, Gillessen Sommer Silke, Touvrey Cedric, Speiser Daniel E
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma
Gallerani E, D'Incalci M, Sala F, Cereda R, Marsoni S, de Braud F, Driessen C, Böhm S, Martinelli G, Delmonte A, Hess U, Noberasco C, Marangon E, Brunelli D, Zucchetti M, Sessa C. A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. Eur J Cancer 2012; 49:290-6.
Oct 8, 2012A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma
Oct 8, 2012Eur J Cancer 2012; 49:290-6
Gallerani Elisa, D'Incalci Maurizio, Sala Federica, Cereda Roberta, Marsoni Silvia, de Braud Filippo, Driessen Christoph, Böhm Steffen, Martinelli Giovanni, Delmonte Angelo, Hess Urs, Noberasco Cristina, Marangon Elena, Brunelli Dario, Zucchetti Massimo, Sessa Cristiana
A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours
Gillessen S, Speiser D, Laurent J, Kramer D, Liedert B, Mattiacci M, Omlin A, Sessa C, Beck J, Gallerani E, Gnad-Vogt U, Stupp R. A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours. Eur J Cancer 2012; 49:35-44.
Aug 20, 2012A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours
Aug 20, 2012Eur J Cancer 2012; 49:35-44
Gillessen Silke, Speiser Daniel E, Laurent Julien, Kramer Daniel, Liedert Bernd, Mattiacci Maria R, Omlin Aurelius, Sessa Cristiana, Beck Joachim, Gallerani Elisa, Gnad-Vogt Ulrike S, Stupp Roger
Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma
Saletti P, Sessa C, De Dosso S, Cerny T, Renggli V, Köberle D. Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma. Oncology 2011; 81:50-4.
Sep 15, 2011Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma
Sep 15, 2011Oncology 2011; 81:50-4
Saletti Piercarlo, Sessa Cristiana, De Dosso Sara, Cerny Thomas, Renggli Verena, Köberle Dieter
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine
Perotti A, Haluska F, Rivera V, Berk L, Corradino I, Marsoni S, Albanell J, Rojo F, Cresta S, Cerny T, Maur M, Capri G, Viganò L, Hess D, Sessa C, Locatelli A, Gianni L. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. J Clin Oncol 2010; 28:4554-61.
Sep 20, 2010Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine
Sep 20, 2010J Clin Oncol 2010; 28:4554-61
Perotti Antonella, Haluska Frank, Rivera Victor M, Berk Lori, Corradino Irene, Marsoni Silvia, Albanell Joan, Rojo Federico, Cresta Sara, Cerny Thomas, Maur Michela, Capri Giuseppe, Viganò Lucia, Hess Dagmar, Sessa Cristiana, Locatelli Alberta, Gianni Luca
A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function
Siano M, Gallino A, Sessa C, Mora O, Leoncini L, Oberson M, Rodriguez-Abreu D, Zucca E, Negretti L, Lerch E, Ghielmini M. A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function. Clinical cancer research : an official journal of the American Association for Cancer Research 2008; 14:7935-9.
Dec 1, 2008A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function
Dec 1, 2008Clinical cancer research : an official journal of the American Association for Cancer Research 2008; 14:7935-9
Siano Marco, Gallino Augusto, Sessa Cristiana, Mora Oreste, Leoncini Leda, Oberson Michel, Rodriguez-Abreu Delvys, Zucca Emanuele, Negretti Laura, Lerch Erika, Ghielmini Michele